Last 12 months
Inside the activity.
0 purchase rows · 23 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 5 |
| Jun 2026 | 0 | 17 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 27, 2025 Filed Aug 30, 2025 00:35 UTC |
Szot Matthew KChief Financial Officer
|
SaleCommon Stock | 1,600 | $14.00 | $22,392.00 |
DisclosureSEC source: 0001213900-25-082821 · ownership.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,733 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 through $14.00. The reporting person undertakes to provide to Cadrenal Therapeutics, Inc., any security holder of Cadrenal Therapeutics, Inc. or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 21:51 UTC |
Ferguson James J. IIIChief Medical Officer
|
GrantStock Options · Derivative | 60,000 | $0.00 Strike: $19.75 | $0.00 |
DisclosureSEC source: 0001213900-25-010973 · ownership.xml · derivative · entry 1 Ferguson James J. III · CIK 0001769041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-02-04 F1 · security: Consists of options to purchase 60,000 shares of common stock, which shall vest 1/4 on March 1, 2026 and thereafter pro rata on a monthly basis over three years, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to the fair market value of the Issuer's common stock on the effective date of the grant. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 18:11 UTC |
Cole Jeffrey ScottChief Operating Officer
|
GrantStock Options · Derivative | 25,000 | $0.00 Strike: $19.79 | $0.00 |
DisclosureSEC source: 0001213900-25-006635 · ownership.xml · derivative · entry 1 Cole Jeffrey Scott · CIK 0001751100 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-01-22 F1 · security: Consists of options to purchase 25,000 shares of common stock, which shall vest 1/4 on February 1, 2026 and thereafter pro rata on a monthly basis over three years, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to the fair market value of the Issuer's common stock on the effective date of the grant. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 18:13 UTC |
WILSON GLYNNDirector
|
GrantStock Options · Derivative | 20,000 | $0.00 Strike: $19.79 | $0.00 |
DisclosureSEC source: 0001213900-25-006639 · ownership.xml · derivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-01-22 F1 · security: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2025. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 23:10 UTC |
Pham Quang XDirector · CEO and Chairman · 10% owner
|
GrantStock Options · Derivative | 65,000 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0001213900-25-006630 · ownership.xml · derivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-01-22 F1 · security: Consists of options to purchase 65,000 shares of common stock, which shall vest 1/4 on February 1, 2026 and thereafter pro rata on a monthly basis over three years, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to 110% of the fair market value of the Issuer's common stock on the effective date of the grant. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 23:10 UTC |
Szot Matthew KChief Financial Officer
|
GrantStock Options · Derivative | 50,000 | $0.00 Strike: $19.79 | $0.00 |
DisclosureSEC source: 0001213900-25-006633 · ownership.xml · derivative · entry 1 Szot Matthew K · CIK 0001401385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-01-22 F1 · security: Consists of options to purchase 50,000 shares of common stock, which shall vest 1/4 on February 1, 2026 and thereafter pro rata on a monthly basis over three years, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to the fair market value of the Issuer's common stock on the effective date of the grant. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 23:13 UTC |
MURPHY JOHN RAYMONDDirector
|
GrantStock Options · Derivative | 20,000 | $0.00 Strike: $19.79 | $0.00 |
DisclosureSEC source: 0001213900-25-006640 · ownership.xml · derivative · entry 1 MURPHY JOHN RAYMOND · CIK 0001275195 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-01-22 F1 · security: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2025. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 18:12 UTC |
Zelenkofske StevenDirector
|
GrantStock Options · Derivative | 20,000 | $0.00 Strike: $19.79 | $0.00 |
DisclosureSEC source: 0001213900-25-006638 · ownership.xml · derivative · entry 1 Zelenkofske Steven · CIK 0001578333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-01-22 F1 · security: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2025. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 18:09 UTC |
Lisicki RobertDirector
|
GrantStock Options · Derivative | 20,000 | $0.00 Strike: $19.79 | $0.00 |
DisclosureSEC source: 0001213900-25-006628 · ownership.xml · derivative · entry 1 Lisicki Robert · CIK 0001779614 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-01-22 F1 · security: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2025. Read SEC document |
| January 23, 2025 Filed Mar 25, 2025 00:38 UTC Amendment |
Pham Quang XDirector · CEO and Chairman · 10% owner
|
GrantStock Options · Derivative | 65,000 | $0.00 Strike: $19.79 | $0.00 |
DisclosureSEC source: 0001013762-25-001779 · ownership.xml · derivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2035-01-22 F1 · security: This amendment to Form 4 is being filed to correct the exercise price and the expiration date of the stock option, which were incorrectly reported on the original Form 4 filed by the Reporting Person on January 24, 2025 (the "Original Form 4"). The exercise price of the stock option is equal to 100% of the fair market value of the Issuer's common stock on the effective date of the grant and the stock option expires ten years from the date of issuance. The stock option vests according to the vesting schedule as previously reported on the Original Form 4. Read SEC document |
| April 10, 2024 Filed Apr 10, 2024 21:30 UTC |
Pham Quang XDirector · CEO and Chairman · 10% owner
|
GiftCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-031923 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,275,000 F1 · shares: On April 10, 2024 Quang Pham transferred an aggregate of 50,000 shares of common stock to a non-for-profit organization, as a gift for no value received, pursuant to a written agreement with the organizations signed by a representative of such organization and Mr. Pham. Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 17:21 UTC |
Cole Jeffrey ScottChief Operating Officer
|
GrantStock Options · Derivative | 150,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001213900-24-029930 · ownership.xml · derivative · entry 1 Cole Jeffrey Scott · CIK 0001751100 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-04-01 F1 · security: Consists of options to purchase 150,000 shares of common stock, which shall vest 1/4 on April 1, 2025 and thereafter pro rata on a monthly basis over three years, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to the fair market value of the Issuer's common stock on the effective date of the grant. F1 · derivative.underlying_shares: Consists of options to purchase 150,000 shares of common stock, which shall vest 1/4 on April 1, 2025 and thereafter pro rata on a monthly basis over three years, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to the fair market value of the Issuer's common stock on the effective date of the grant. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 19:38 UTC |
WILSON GLYNNDirector
|
GrantStock Options · Derivative | 70,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001213900-24-004996 · ownership.xml · derivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2034-01-17 F1 · security: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2024 and vesting fully on January 18, 2025. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2024 and vesting fully on January 18, 2025. Read SEC document |
| January 18, 2024 Filed Jan 20, 2024 00:40 UTC |
Pham Quang XDirector · Chief Executive Officer · 10% owner
|
GrantStock Options · Derivative | 150,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001213900-24-005001 · ownership.xml · derivative · entry 1 Pham Quang X · CIK 0001405290 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-01-17 F1 · security: These options vest 25% on February 1, 2025 and thereafter pro rata on a monthly basis for the next 36 months. F1 · derivative.exercise_date: These options vest 25% on February 1, 2025 and thereafter pro rata on a monthly basis for the next 36 months. Read SEC document |
| January 18, 2024 Filed Jan 20, 2024 00:39 UTC |
Szot Matthew KChief Financial Officer
|
GrantStock Options · Derivative | 250,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001213900-24-004999 · ownership.xml · derivative · entry 1 Szot Matthew K · CIK 0001401385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2034-01-17 F1 · security: These options vest 25% on February 1, 2025 and thereafter pro rata on a monthly basis for the next 36 months. F1 · derivative.exercise_date: These options vest 25% on February 1, 2025 and thereafter pro rata on a monthly basis for the next 36 months. Read SEC document |
| January 18, 2024 Filed Jan 20, 2024 00:41 UTC |
MURPHY JOHN RAYMONDDirector
|
GrantStock Options · Derivative | 100,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001213900-24-005003 · ownership.xml · derivative · entry 1 MURPHY JOHN RAYMOND · CIK 0001275195 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-01-17 F1 · security: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2024 and vesting fully on January 18, 2025. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2024 and vesting fully on January 18, 2025. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 19:41 UTC |
Zelenkofske StevenDirector
|
GrantStock Options · Derivative | 100,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001213900-24-005004 · ownership.xml · derivative · entry 1 Zelenkofske Steven · CIK 0001578333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-01-17 F1 · security: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2024 and vesting fully on January 18, 2025. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2024 and vesting fully on January 18, 2025. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 19:38 UTC |
LOSORDO DOUGLAS WChief Medical Officer
|
GrantStock Options · Derivative | 150,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001213900-24-004994 · ownership.xml · derivative · entry 1 LOSORDO DOUGLAS W · CIK 0001583810 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-01-17 F1 · security: These options vest 25% on February 1, 2025 and thereafter pro rata on a monthly basis for the next 36 months. F1 · derivative.exercise_date: These options vest 25% on February 1, 2025 and thereafter pro rata on a monthly basis for the next 36 months. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 19:41 UTC |
Lisicki RobertDirector
|
GrantStock Options · Derivative | 50,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001213900-24-005002 · ownership.xml · derivative · entry 1 Lisicki Robert · CIK 0001779614 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-01-17 F1 · security: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2024 and vesting fully on January 18, 2025. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2024 and vesting fully on January 18, 2025. Read SEC document |
| October 23, 2023 Filed Feb 13, 2024 02:41 UTC |
Pham Quang XDirector · CEO and Chairman · 10% owner
|
GiftCommon Stock | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-012837 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,325,000 F1 · shares: On October 23, 2023, Quang Pham transferred an aggregate of 85,000 shares of common stock to three non-for-profit organizations, as gifts for no value received, pursuant to a written agreement with each of the three organizations signed by a representative of each such organization and Mr. Pham. Read SEC document |
| October 05, 2023 Filed Oct 6, 2023 21:32 UTC |
MURPHY JOHN RAYMONDDirector
|
PurchaseCommon Stock | 2,669 | $0.69 | $1,841.61 |
DisclosureSEC source: 0001213900-23-081216 · ownership.xml · nonDerivative · entry 2 MURPHY JOHN RAYMOND · CIK 0001275195 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 614,792 Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 21:32 UTC |
MURPHY JOHN RAYMONDDirector
|
PurchaseCommon Stock | 17,331 | $0.70 | $12,131.70 |
DisclosureSEC source: 0001213900-23-081216 · ownership.xml · nonDerivative · entry 1 MURPHY JOHN RAYMOND · CIK 0001275195 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 612,123 Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 19:28 UTC |
Pham Quang XDirector · CEO and Chairman · 10% owner
|
PurchaseCommon Stock | 20,000 | $0.90 | $17,988.00 |
DisclosureSEC source: 0001213900-23-074336 · ownership.xml · nonDerivative · entry 2 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,410,000 Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 19:28 UTC |
Pham Quang XDirector · CEO and Chairman · 10% owner
|
PurchaseCommon Stock | 20,000 | $0.91 | $18,200.00 |
DisclosureSEC source: 0001213900-23-074336 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,390,000 Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 10:05 UTC |
Pham Quang XDirector · CEO and Chairman · 10% owner
|
PurchaseCommon Stock | 10,000 | $0.84 | $8,433.00 |
DisclosureSEC source: 0001213900-23-073551 · ownership.xml · nonDerivative · entry 5 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,370,000 Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 10:05 UTC |
Pham Quang XDirector · CEO and Chairman · 10% owner
|
PurchaseCommon Stock | 10,000 | $0.92 | $9,168.00 |
DisclosureSEC source: 0001213900-23-073551 · ownership.xml · nonDerivative · entry 4 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,360,000 Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 10:05 UTC |
Pham Quang XDirector · CEO and Chairman · 10% owner
|
PurchaseCommon Stock | 20,000 | $0.92 | $18,444.00 |
DisclosureSEC source: 0001213900-23-073551 · ownership.xml · nonDerivative · entry 3 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,350,000 Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 10:05 UTC |
Pham Quang XDirector · CEO and Chairman · 10% owner
|
PurchaseCommon Stock | 20,000 | $0.93 | $18,582.00 |
DisclosureSEC source: 0001213900-23-073551 · ownership.xml · nonDerivative · entry 2 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,330,000 Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 10:05 UTC |
Pham Quang XDirector · CEO and Chairman · 10% owner
|
PurchaseCommon Stock | 10,000 | $0.93 | $9,318.00 |
DisclosureSEC source: 0001213900-23-073551 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,310,000 Read SEC document |
| July 23, 2023 Filed Jul 24, 2023 17:26 UTC |
Lisicki RobertDirector
|
GrantStock options · Derivative | 75,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001213900-23-059274 · ownership.xml · derivative · entry 1 Lisicki Robert · CIK 0001779614 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-07-23 F1 · shares: Consists of options to purchase 75,000 shares of common stock, which shall vest over a period of three years, with 1/3 vesting on August 1, 2024 and thereafter 1/36 on a monthly basis. Read SEC document |
| March 21, 2023 Filed Mar 22, 2023 20:01 UTC |
MURPHY JOHN RAYMONDDirector
|
PurchaseCommon Stock | 10,000 | $1.39 | $13,900.00 |
DisclosureSEC source: 0001213900-23-022065 · ownership.xml · nonDerivative · entry 1 MURPHY JOHN RAYMOND · CIK 0001275195 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 594,792 F1 · balance_after: The amount of securities beneficially owned by Mr. Murphy following the reported transaction is correctly reported on this Form 4. The amount of securities beneficially owned by Mr. Murphy has been adjusted to correct immaterial errors in prior Form 4 filings that were filed with the Securities and Exchange Commission on January 24, 2023 and March 16, 2023. Read SEC document |
| March 16, 2023 Filed Mar 16, 2023 21:27 UTC |
MURPHY JOHN RAYMONDDirector
|
PurchaseCommon Stock | 20,000 | $1.67 | $33,398.00 |
DisclosureSEC source: 0001213900-23-020675 · ownership.xml · nonDerivative · entry 1 MURPHY JOHN RAYMOND · CIK 0001275195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 574,792 Read SEC document |
| February 10, 2023 Filed Feb 13, 2023 14:00 UTC |
Pham Quang XDirector · CEO and Chairman · 10% owner
|
GrantCommon Stock | 25,000 | $1.94 | $48,500.00 |
DisclosureSEC source: 0001213900-23-010504 · ownership.xml · nonDerivative · entry 1 Pham Quang X · CIK 0001405290 · Director · CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300,000 Read SEC document |
| January 24, 2023 Filed Jan 24, 2023 17:02 UTC |
WILSON GLYNNDirector
|
ConversionConvertible Promissory Note · Derivative | 50,000 | Not disclosed Strike: $1.00 | Not disclosed |
DisclosureSEC source: 0001213900-23-004886 · ownership.xml · derivative · entry 2 WILSON GLYNN · CIK 0001405625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon consummation of the initial public offering of Cadrenal Therapeutics, Inc. on January 24, 2023, Dr. Wilson was issued 50,000 shares of common stock pursuant to the conversion of a convertible promissory note in the principal amount of $50,000, based on a conversion price of $1.00 per share. F1 · derivative.exercise_date: Upon consummation of the initial public offering of Cadrenal Therapeutics, Inc. on January 24, 2023, Dr. Wilson was issued 50,000 shares of common stock pursuant to the conversion of a convertible promissory note in the principal amount of $50,000, based on a conversion price of $1.00 per share. F1 · derivative.expiration_date: Upon consummation of the initial public offering of Cadrenal Therapeutics, Inc. on January 24, 2023, Dr. Wilson was issued 50,000 shares of common stock pursuant to the conversion of a convertible promissory note in the principal amount of $50,000, based on a conversion price of $1.00 per share. Read SEC document |
| January 24, 2023 Filed Jan 24, 2023 17:02 UTC |
WILSON GLYNNDirector
|
ConversionCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-004886 · ownership.xml · nonDerivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon consummation of the initial public offering of Cadrenal Therapeutics, Inc. on January 24, 2023, Dr. Wilson was issued 50,000 shares of common stock pursuant to the conversion of a convertible promissory note in the principal amount of $50,000, based on a conversion price of $1.00 per share. Read SEC document |
| January 24, 2023 Filed Jan 24, 2023 22:01 UTC |
Szot Matthew KChief Financial Officer
|
GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-004883 · ownership.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Read SEC document |
| January 24, 2023 Filed Jan 24, 2023 22:00 UTC |
MURPHY JOHN RAYMONDDirector
|
ConversionConvertible Promissory Note · Derivative | 514,792 | Not disclosed Strike: $1.00 | Not disclosed |
DisclosureSEC source: 0001213900-23-004882 · ownership.xml · derivative · entry 2 MURPHY JOHN RAYMOND · CIK 0001275195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 514,792 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon consummation of the initial public offering of Cadrenal Therapeutics, Inc. on January 24, 2023, Mr. Murphy was issued 514,792 shares of common stock pursuant to the conversion of a convertible promissory note in the principal amount of $500,000, based on a conversion price of $1.00 per share. F1 · derivative.exercise_date: Upon consummation of the initial public offering of Cadrenal Therapeutics, Inc. on January 24, 2023, Mr. Murphy was issued 514,792 shares of common stock pursuant to the conversion of a convertible promissory note in the principal amount of $500,000, based on a conversion price of $1.00 per share. F1 · derivative.expiration_date: Upon consummation of the initial public offering of Cadrenal Therapeutics, Inc. on January 24, 2023, Mr. Murphy was issued 514,792 shares of common stock pursuant to the conversion of a convertible promissory note in the principal amount of $500,000, based on a conversion price of $1.00 per share. Read SEC document |
| January 24, 2023 Filed Jan 24, 2023 22:00 UTC |
MURPHY JOHN RAYMONDDirector
|
ConversionCommon Stock | 514,792 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-004882 · ownership.xml · nonDerivative · entry 1 MURPHY JOHN RAYMOND · CIK 0001275195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 554,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon consummation of the initial public offering of Cadrenal Therapeutics, Inc. on January 24, 2023, Mr. Murphy was issued 514,792 shares of common stock pursuant to the conversion of a convertible promissory note in the principal amount of $500,000, based on a conversion price of $1.00 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.